Unidade Local De Saude De Lisboa Ocidental E.P.E.
- Address
- lock Available on a paid plan
Cardiovascular Research
At Unidade Local De Saude De Lisboa Ocidental E.P.E., clinical trials in cardiovascular diseases focus on major conditions such as atrial fibrillation, heart failure, hypertension, and broader atherosclerotic cardiovascular disease. The studies are designed to test new treatment options and measure whether they can reduce serious heart- and stroke-related events.
- Prevention of stroke, heart attack, and other major cardiovascular events
- Management of established vascular disease and high cardiovascular risk
- Evaluation of therapies for heart failure, cardiomyopathy, and lipid-related risk
This work reflects a strong interest in improving long-term outcomes for people with complex cardiovascular conditions.
Kidney Disease and Nephrology
The Serviço de Nefrologia is actively involved in studies across nutritional and metabolic diseases and reproductive and urinary physiological phenomena, with a strong emphasis on chronic kidney disease, IgA nephropathy, focal segmental glomerulosclerosis, and autosomal dominant polycystic kidney disease. These trials aim to slow kidney decline, reduce proteinuria, and improve kidney-related outcomes.
- Testing new approaches for proteinuria and kidney function preservation
- Studying progressive kidney diseases and inherited renal disorders
- Assessing therapies intended to delay worsening kidney disease
The site’s nephrology research also includes patients with advanced kidney disease and transplant-related complications, showing broad clinical engagement in renal care.
Immune-Mediated and Inflammatory Conditions
Several trials at this hospital/clinic explore immune system diseases such as lupus nephritis and other inflammatory kidney disorders. The research is centered on evaluating whether targeted therapies can better control immune-driven damage and improve renal response.
- Immune-related kidney inflammation and autoimmune renal disease
- Measures of proteinuria and renal response in active disease
- Safety and effectiveness of newer immune-targeted treatments
These studies are important for patients whose kidney disease is linked to abnormal immune activity and persistent inflammation.
Transplantation and Advanced Renal Care
Research at Unidade Local De Saude De Lisboa Ocidental E.P.E. also addresses outcomes after kidney transplantation, including delayed graft function and other high-risk post-transplant challenges. The goal is to improve recovery after transplant and support better function of the donated kidney.
- Reducing complications after deceased-donor kidney transplantation
- Improving early graft recovery and dialysis-free outcomes
- Evaluating therapies for transplant-related kidney injury
This area complements the site’s broader nephrology program by focusing on recovery, safety, and better long-term transplant success.
Metabolic and Cardiometabolic Risk
Another important part of the trial portfolio involves nutritional and metabolic diseases linked to kidney and heart health, including studies in obesity, elevated lipoprotein(a), and other cardiometabolic risk factors. These trials are designed to see whether new therapies can lower risk and protect both the heart and kidneys.
- Cardiometabolic risk reduction in people with kidney disease or vascular disease
- Evaluation of treatments for inflammation, lipids, and blood pressure control
- Prevention of future cardiovascular and renal complications
The research combines prevention and treatment goals, linking metabolic health with cardiovascular and renal protection.
Pediatric and Specialized Cardiovascular-Kidney Studies
The site also contributes to selected studies in children and other specialized populations, including pediatric pulmonary arterial hypertension and pediatric left ventricular systolic dysfunction. These trials focus on whether treatments are safe and effective in younger patients with serious heart or kidney-related conditions.
- Children with pulmonary vascular disease
- Pediatric heart failure and ventricular dysfunction
- Long-term safety and symptom improvement in specialized groups
By participating in these studies, the center supports research that extends beyond adult nephrology into carefully selected pediatric and cardiopulmonary conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 165 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 163 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 31 by active trials.
- 1Novartis Pharma AG5active
lock +30 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG12trials
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Unidade Local De Saude De Lisboa Ocidental E.P.E.
lock Showing 1 of 105 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 165 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2020-03-17 | 2025-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
